Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

PYK2 promotes HER2-positive breast cancer invasion.

Al-Juboori SI, Vadakekolathu J, Idri S, Wagner S, Zafeiris D, Pearson JR, Almshayakhchi R, Caraglia M, Desiderio V, Miles AK, Boocock DJ, Ball GR, Regad T.

J Exp Clin Cancer Res. 2019 May 22;38(1):210. doi: 10.1186/s13046-019-1221-0.

2.

A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study.

Wagner S, Vadakekolathu J, Tasian SK, Altmann H, Bornhäuser M, Pockley AG, Ball GR, Rutella S.

Blood Adv. 2019 Apr 23;3(8):1330-1346. doi: 10.1182/bloodadvances.2018030726.

3.

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.

Thompson AM, Clements K, Cheung S, Pinder SE, Lawrence G, Sawyer E, Kearins O, Ball GR, Tomlinson I, Hanby A, Thomas JSJ, Maxwell AJ, Wallis MG, Dodwell DJ; Sloane Project Steering Group (NHS Prospective Study of Screen-Detected Non-invasive Neoplasias).

Eur J Cancer. 2018 Sep;101:210-219. doi: 10.1016/j.ejca.2018.06.027. Epub 2018 Aug 6.

PMID:
30092498
4.

The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.

Abdel-Fatah TMA, Rees RC, Pockley AG, Moseley P, Ball GR, Chan SYT, Ellis IO, Miles AK.

Oncotarget. 2017 Nov 18;8(68):112245-112257. doi: 10.18632/oncotarget.22496. eCollection 2017 Dec 22.

5.

Multicentre study of patient-reported and clinical outcomes following immediate and delayed Autologous Breast Reconstruction And Radiotherapy (ABRAR study).

Steele KH, Macmillan RD, Ball GR, Akerlund M, McCulley SJ.

J Plast Reconstr Aesthet Surg. 2018 Feb;71(2):185-193. doi: 10.1016/j.bjps.2017.10.030. Epub 2017 Nov 10.

PMID:
29203259
6.

Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.

Arora A, Parvathaneni S, Aleskandarany MA, Agarwal D, Ali R, Abdel-Fatah T, Green AR, Ball GR, Rakha EA, Ellis IO, Sharma S, Madhusudan S.

Mol Cancer Ther. 2017 Jan;16(1):239-250. doi: 10.1158/1535-7163.MCT-16-0290. Epub 2016 Nov 11.

7.

Glucolipotoxicity initiates pancreatic β-cell death through TNFR5/CD40-mediated STAT1 and NF-κB activation.

Bagnati M, Ogunkolade BW, Marshall C, Tucci C, Hanna K, Jones TA, Bugliani M, Nedjai B, Caton PW, Kieswich J, Yaqoob MM, Ball GR, Marchetti P, Hitman GA, Turner MD.

Cell Death Dis. 2016 Aug 11;7(8):e2329. doi: 10.1038/cddis.2016.203.

8.

Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.

Green AR, Soria D, Stephen J, Powe DG, Nolan CC, Kunkler I, Thomas J, Kerr GR, Jack W, Cameron D, Piper T, Ball GR, Garibaldi JM, Rakha EA, Bartlett JM, Ellis IO.

J Pathol Clin Res. 2016 Jan 15;2(1):32-40. doi: 10.1002/cjp2.32. eCollection 2016 Jan.

9.

SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.

Abdel-Fatah TMA, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, Rees RC, Caldas C, Ellis IO, Ball GR, Chan SYT.

Lancet Oncol. 2016 Jul;17(7):1004-1018. doi: 10.1016/S1470-2045(16)00174-1. Epub 2016 Jun 14.

PMID:
27312051
10.

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Madhusudan S, Ellis IO, Rakha EA.

Br J Cancer. 2016 Apr 12;114(8):917-28. doi: 10.1038/bjc.2016.46. Epub 2016 Mar 8.

11.

Accuracy of GE digital breast tomosynthesis vs supplementary mammographic views for diagnosis of screen-detected soft-tissue breast lesions.

Cornford EJ, Turnbull AE, James JJ, Tsang R, Akram T, Burrell HC, Hamilton LJ, Tennant SL, Bagnall MJ, Puri S, Ball GR, Chen Y, Jones V.

Br J Radiol. 2016;89(1058):20150735. doi: 10.1259/bjr.20150735. Epub 2015 Nov 11.

12.

HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.

Abdel-Fatah TM, McArdle SE, Agarwal D, Moseley PM, Green AR, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Clin Cancer Res. 2016 Feb 15;22(4):905-14. doi: 10.1158/1078-0432.CCR-15-0610. Epub 2015 Aug 3.

14.

Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer.

Coveney C, Boocock DJ, Rees RC, Deen S, Ball GR.

Microarrays (Basel). 2015 Jul 17;4(3):324-38. doi: 10.3390/microarrays4030324.

15.

Artificial neural network inference (ANNI): a study on gene-gene interaction for biomarkers in childhood sarcomas.

Tong DL, Boocock DJ, Dhondalay GK, Lemetre C, Ball GR.

PLoS One. 2014 Jul 15;9(7):e102483. doi: 10.1371/journal.pone.0102483. eCollection 2014.

16.

DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.

Powe DG, Dhondalay GK, Lemetre C, Allen T, Habashy HO, Ellis IO, Rees R, Ball GR.

PLoS One. 2014 Jan 2;9(1):e84428. doi: 10.1371/journal.pone.0084428. eCollection 2014.

17.

A quantifier-based fuzzy classification system for breast cancer patients.

Soria D, Garibaldi JM, Green AR, Powe DG, Nolan CC, Lemetre C, Ball GR, Ellis IO.

Artif Intell Med. 2013 Jul;58(3):175-84. doi: 10.1016/j.artmed.2013.04.006. Epub 2013 Jun 18.

PMID:
23791088
18.

Biomarker identification in breast cancer: Beta-adrenergic receptor signaling and pathways to therapeutic response.

Kafetzopoulou LE, Boocock DJ, Dhondalay GK, Powe DG, Ball GR.

Comput Struct Biotechnol J. 2013 May 21;6:e201303003. doi: 10.5936/csbj.201303003. eCollection 2013.

19.

Identification of novel breast cancer-associated transcripts by UniGene database mining and gene expression analysis in normal and malignant cells.

Laversin SA, Phatak VM, Powe DG, Li G, Miles AK, Hughes DC, Ball GR, Ellis IO, Gritzapis AD, Missitzis I, McArdle SE, Rees RC.

Genes Chromosomes Cancer. 2013 Mar;52(3):316-29. doi: 10.1002/gcc.22031. Epub 2012 Dec 8.

PMID:
23225347
20.

TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome.

Aleskandarany MA, Negm OH, Rakha EA, Ahmed MA, Nolan CC, Ball GR, Caldas C, Green AR, Tighe PJ, Ellis IO.

Breast Cancer Res Treat. 2012 Nov;136(2):419-27. doi: 10.1007/s10549-012-2249-4. Epub 2012 Oct 4.

PMID:
23053644

Supplemental Content

Loading ...
Support Center